Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05668611
Other study ID # 2022-0312
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 3, 2023
Est. completion date December 20, 2023

Study information

Verified date February 2024
Source Children's Hospital Medical Center, Cincinnati
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The first primary objective of this study is to determine the diagnostic performance (sensitivity and specificity) of primary MOH nurses who have completed certification in focused echocardiography acquisition and interpretation by expert trainers to accurately identify patients who are screen positive and screen negative for rheumatic heart disease. The second primary objective is to determine the diagnostic performance (sensitivity and specificity) of secondary MOH nurses who have completed certification in focused echocardiography acquisition and interpretation by MOH nurse trainers to accurately identify patients who are screen positive and screen negative for rheumatic heart disease.


Description:

Objective 1: 4 ultrasound naïve nurses (Primary) employed at the HCIII/IVs participating in ADD-RHD Part 1 (SOMREC REF 2021-61) in Lira, will be trained and certified by experts in echocardiography for RHD on focused RHD echocardiographic screening examination and interpretation using a novel AI guided software. Focused RHD screening echocardiograms by the 4 nurses will be integrated into routine clinical practice at their assigned HCIII/IVs for 1 month. Screen positive patients will be referred to LRRH for confirmatory echocardiogram using a Standard echocardiographic machine under the National RHD registry (SOMREC REF 2014-137). All echocardiograms will be uploaded to a secure cloud-based server and over-read by a cardiologist with in one - two (1 - 2) weeks to ensure patient safety and to determine trainee performance. Diagnostic accuracy, sensitivity, specificity, positive and negative predictive values will be calculated. 4 MOH trainees will use pre-recorded PowerPoint presentations to conduct hands-on training for phase 2 (secondary) nurses. Objective 2: Similar to Phase 1 with just a few exceptions. 12 MOH nurses will be trained and certified by MOH nurse trainers from phase 1 to acquire and interpret RHD focused screening echocardiograms using a novel AI guided software. Screening will be integrated into routine care for 2 months and diagnostic performance assessed.


Recruitment information / eligibility

Status Completed
Enrollment 1628
Est. completion date December 20, 2023
Est. primary completion date December 20, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years to 40 Years
Eligibility Inclusion Criteria: - Attend same HCIII/IV sites that the MOH nurses work at - Agree to participate via the study's informed consent Exclusion Criteria: - Very sick participants requiring transfer to higher level facility or inpatient care

Study Design


Intervention

Other:
Primary Training Phase
A four-day training program taken over the course of two weekends will include materials on RHD and RHD echocardiographic screening using focused artificial intelligence navigational guided echocardiographic acquisition to identify patients who are screen positive or screen negative for RHD. The echo protocol will be limited to the parasternal long axis-view (2D and color Doppler) focusing on mitral and aortic valve morphology and function and a single 2D apical 4 chamber view for auto EF. The curriculum package will include online modules, instructor delivered PowerPoint presentations, and hands on practice on volunteers with and without RHD.
Primary Assessment Phase
A pre- and post-training test on RHD knowledge and diagnosis will be administered. A rapid competency assessment, including obtaining imaging on volunteers with or without RHD and an online test with pre-recorded cases of RHD, LV dysfunction and Pericardial effusions, will be utilized at the end of the 4-day training sessions. Trainees will be monitored by trained study personnel and at the end of the practicum training, the expert users will blindly review and assess the quality of each study using the standardized scale and competency scorecard provided below. Additionally, they will be asked to pass the knowledge quiz (80% or better). If competency is not achieved, an additional weekend of training can be added.
Primary Screening Phase
Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care. Screening will be done daily over a period of one month. A minimum total of 400 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants (at least 5 participants per day). At the end of each screen, the trainees will interpret the screen as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo. At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks.
Secondary Training Phase
Each Primary Trained MOH Nurse will train 3 other nurses from their Health Center using pre-recorded PowerPoints.
Secondary Assessment Phase
The secondarily trained nurses will be assessed and certified by the nurse trainer.
Secondary Screening Phase
Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care. Screening will be done daily over a period of two months. A minimum total of 1200 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants. At the end of each screen, the trainees will interpret the study as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo. At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks.

Locations

Country Name City State
Uganda Uganda Heart Institute Kampala

Sponsors (2)

Lead Sponsor Collaborator
Children's Hospital Medical Center, Cincinnati Uganda Heart Institute

Country where clinical trial is conducted

Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Primary RHD Echocardiographic Diagnostic accuracy, sensitivity, specificity of MOH nurses Diagnostic performance of MOH nurses who have completed certification in focused echocardiography acquisition and interpretation by expert trainers will be assessed. Diagnostic accuracy, sensitivity, specificity, positive and negative predictive values will be calculated to determine diagnostic performance of MOH nurses who have completed certification on focused echocardiography acquisition and interpretation. The ability of trainees to correctly identify screen positive and negative patients for RHD using known expert diagnosis as the reference. Correct determination of RHD screen positive/negative in at least 80% of cases is the benchmark 2 months after completion of training
Secondary Knowledge Assessment Questionnaire to test compare pre and post training knowledge about Rheumatic Heart Disease administered to nurse trainees. Immediately before the training session and immediately after completion of training
Secondary Computer Based Testing Computer based testing designed to determine positive and negative screening referrals of patients with RHD and other cardiac diseases Immediately following training
Secondary Rapid Competency assessment This assessment will be administered post training to nurse trainees. It is an observation- based assessment designed to assess correct use of the technology, basic image acquisition proficiency, diagnostic accuracy and image quality. Immediately following training
Secondary Provider satisfaction Surveys questions on training and screening experience along with guided discussions on the training and screening experiences will be administered to nurse trainees Immediately post training
Secondary Longitudinal Image Quality Expert Echocardiographers will access each image acquired by nurses using the ACEP scale. A scale of 1-5 (1) being no recognizable structure and (5) being excellent image quality of all structures. A score of 3 and above will be considered diagnostic. Daily assessment for 1 month
Secondary Provider confidence Nurses will subjectively report their level of confidence regarding image quality. The levels of confidence will be assessed. (1) Very confident, image quality is good and adequate for diagnosis. (2) Fairly confident, image is good but confirmation of diagnosis by expert trainer needed, (3) Not confident, image quality not adequate. Daily assessment for 1 month
Secondary Diagnostic performance for other common categories of cardiac diseases Assess nurse's ability to accurately identify left ventricular dysfunction and pericardial effusion as compared to the same standard applied by an expert. Through completion of screening phase, average of 1 month
Secondary Time to certification Determine the time from the first day of training to certification for participants including remediation time. Trough first day of training to study completion, average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05991219 - Screening and Secondary Prevention Rheumatic Heart Disease Study
Completed NCT02661763 - Rheumatic Heart Disease Study in Lusaka N/A
Completed NCT02188862 - Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region N/A
Completed NCT01178710 - Effect of Simvastatin on Cardiac Function N/A
Recruiting NCT05693545 - GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial Phase 2
Completed NCT06150274 - Comparison of Wire Assisted Percutaneous Balloon Mitral Valvulotomy With Standard Inoue Balloon Valvulotomy N/A
Terminated NCT03926156 - RIvoraxaban in Mitral Stenosis Phase 3
Recruiting NCT05783375 - Accelerating Delivery of rheUmatic Heart Disease Preventive iNterventions in Northern Uganda N/A
Completed NCT02474108 - Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion and Left Atrium Enlargement N/A
Recruiting NCT04556188 - The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa
Recruiting NCT03991910 - The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients Phase 3
Active, not recruiting NCT03346525 - Determining the Impact of Penicillin in Latent RHD: The GOAL Trial Phase 2
Recruiting NCT05504928 - Effectiveness of a School-centered Prevention Program on Prevalence of Latent Rheumatic Heart Disease N/A
Not yet recruiting NCT03549052 - Right Ventricular Echo Assessment in Mitral Valve Replacement
Recruiting NCT05487469 - Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass N/A
Completed NCT05276999 - Rheumatic Heart Disease Community Streptococcal Treatment Program "RESET" N/A
Active, not recruiting NCT05211024 - A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)
Withdrawn NCT02832531 - INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority Phase 3
Completed NCT01794884 - Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery Phase 2
Completed NCT00264524 - DNA Typing of HLA-DR/DQ Alleles in Taiwan Chinese With Rheumatic Heart Disease N/A